Furthest ahead in the pipeline is tolebrutinib, developed by Paris-based Sanofi to potentially treat SPMS, PPMS and relapsing forms of MS. The investigational agent is an oral central nervous system ...

Exscientia plc (Nasdaq: EXAI) today announced three abstracts to be presented at the 36th EORTC-NCI-AACR (ENA) Symposium 2024 ...

Demonstrated combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies Data highlights ... as well as an additional focus on our assay development, highlight the ...

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced it will share research from studies evaluating BRUKINSA® (zanubrutinib), Bruton tyrosine kinase (BTK) ...

“These posters, as well as an additional focus on our assay development ... the combination potential for MALT1 and BTK inhibitors in models of B-cell malignancies, PD biomarkers related ...

Eli Lilly’s buyout of Loxo Oncology last year has already yielded one approved drug, and it now has a path to market for a second after BTK inhibitor ... go-to therapy in B-cell non-Hodgkin ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Analyst Derek Archila from Wells Fargo maintained a Buy rating on Nurix Therapeutics (NRIX – Research Report) and keeping the price ...

A list of downloadable documents created during development.

Lipsky, MD, moderated a discussion on the efficacy and safety of newer BTK inhibitors used to treat patients with chronic lymphocytic leukemia ... I think that CLL is not the same kind of disease as ...